INTRODUCTION {#S1}
============

The basic unit of chromatin is the nucleosome, which is composed of 146 base pairs of DNA wrapped around an octamer of the four histone molecules, H3, H4, H2A, and H2B. Multiple lysine residues on histone H3 are methylated with one, two or three methyl moieties (me1 to me3) by histone methyltransferases (HMTs) and are removed by histone demethylases (HDMs). Methylation events at different lysine residues (e.g. H3K4 and H3K9) are recognized by specific effectors, or "reader", protein modules, such as PHD ([P]{.ul}lant [H]{.ul}omeo [D]{.ul}omain) fingers for H3K4me3^[@R1]--[@R4]^ and Chromodomains for H3K9me3^[@R5],[@R6]^, which then lead to transcriptional activation or repression, respectively^[@R7]^. Importantly, a number of known or putative HMTs, methyl histone binders, and HDMs have been shown by human genetics studies to be mutated in mental retardation (MR) patients, suggesting important roles for histone methylation dynamics in human brain function^[@R8]--[@R10]^. However, how histone methylation contributes to the development of the human nervous system and brain function is not well understood.

Human *ATRX* encodes an ATP-dependent chromatin remodeling protein^[@R11]^. Male children carrying a mutation in *ATRX* suffer from a broad range of symptoms, including alpha-thalassemia, psychomotor retardation, facial dysmorphia, and genital abnormalities^[@R12]^. The ATR-X syndrome-associated missense mutations are found predominantly in two discrete regions of ATRX protein, the N-terminal ADD (ADD~ATRX~) and the C-terminal ATP-dependent chromatin-remodeling domain^[@R13]^ ([Fig. 1a](#F1){ref-type="fig"}). Missense mutations in the ATPase domain attenuate the ATPase activity of ATRX^[@R14]^. However, the function of ADD~ATRX~ has not been identified. Thus, we sought to uncover the role of ADD~ATRX~ to understand the molecular mechanisms underlying ATR-X etiology. Here we report on structural and *in vivo* functional investigation of ADD~ATRX~ as a novel type of histone H3K9me3 "reader" module, whose H3 binding is required for heterochromatin localization, thus shedding new light on the disease mechanisms.

RESULTS {#S2}
=======

Methylation regulates binding of ADD~ATRX~ to histone H3 {#S3}
--------------------------------------------------------

The ADD domains in DNMT3L and DNMT3A, which are components of the *de novo* DNA methyltransferase complex, have been shown to bind histone H3^[@R15],[@R16]^. To determine whether ATRX also binds histones via its ADD domain, ADD~ATRX~ (aa 161--292) was fused to GST (glutathione-s-transferase), and incubated with a collection of unmethylated or methylated histone peptides. As shown in [Fig. 1b](#F1){ref-type="fig"}, we detected substantial binding of ADD~ATRX~ with the first 21 amino acids of the unmethylated H3 peptide (lane 3), but not with amino acids 2--44 or 69--89 of H3 (lanes 9 and 18) or the H4 tail peptide (lane 22). Consistently, ADD~ATRX~ also preferentially pulled down histone H3 when incubated with bulk histones ([Supplementary Fig. 1a and 1b](#SD1){ref-type="supplementary-material"}). Binding of ADD~ATRX~ to the histone H3 peptide was further enhanced by methylation at Lys9, with trimethylation having the most pronounced effect ([Fig. 1b](#F1){ref-type="fig"}, lanes 4--6). These results suggest that ADD~ATRX~ binds the H3 N-terminal tail and H3K9 methylation augments this interaction.

The ADD~ATRX~/H3 interactions were quantitatively analyzed by ITC (Isothermal Titration Calorimetry) as well as SPR (Surface Plasmon Resonance) assays. The ADD~ATRX~ binds the unmodified H3 tail with a Kd of 3.7μM (ITC, [Fig. 1](#F1){ref-type="fig"}) (3.2 μM by SPR shown in [Supplementary Fig. 1c--1e](#SD1){ref-type="supplementary-material"}). Methylation at H3K9 improved the binding affinity, with trimethylation exhibiting the most pronounced enhancement (factor of 7.4) ([Fig. 1d and f](#F1){ref-type="fig"}) (enhanced affinity by a factor of 3.8 in the SPR assay shown in [Supplementary Fig. 1c--1e](#SD1){ref-type="supplementary-material"}). The nearly doubled enthalpy change (−12.2 kcal/mol vs. −6.1 kcal/mol, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}) associated with binding H3K9me3 versus the unmodified H3 peptide indicates that the recognition of K9me3 group is an enthalpy-driven process. By contrast, methylation at Lys4 dramatically reduced binding in a methyl moiety-dependent manner ([Fig. 1e](#F1){ref-type="fig"}). Furthermore, we calculated a Kd of 4.9 μM when H3 was trimethylated at both Lys4 and Lys9, while retaining the large enthalpy change of about −12.0 kcal/mol ([Fig. 1f](#F1){ref-type="fig"}, [Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The H3K4me3-mediated neutralization of binding enhancement by H3K9me3 suggests possible methylation crosstalk between Lys4 and Lys9. The negative regulation of the ADD~ATRX~/H3 interaction by Lys4 methylation is reminiscent of the previous reports on ADD~DNMT3L~ and ADD~DNMT3A~^[@R15],[@R16]^. An important distinction is that H3K9 trimethylation does not impact histone H3 binding by ADD~DNMT3L~ and ADD~DNMT3A~^[@R15]--[@R17]^. Therefore, the ADD~ATRX~ domain represents a new "reader" module that senses methylation states at both H3K4 and H3K9.

H3K9me3 recruits Atrx on pericentromeric heterochromatin {#S4}
--------------------------------------------------------

Atrx has been shown to mainly localize to heterochromatic regions, including telomeres and pericentromeric heterochromatin (PCH)^[@R18],[@R19]^. H3K9me3 is a hallmark modification of constitutive heterochromatin, such as PCH^[@R20],[@R21]^. In contrast, H3K4me2 and H3K4me3 are largely absent from PCH^[@R22],[@R23]^. To assess the contribution of H3K9me3 to Atrx PCH localization, we utilized double knockout mouse embryonic fibroblast (DKO MEF) cells, which lack the H3K9me3 histone methyltransferases (HMTases) Suv39h1/h2^[@R24],[@R25]^. Both H3K9me3 and the heterochromatin protein, Hp1α (also known as Cbx5), were undetectable at PCH in the DKO MEF cells as previously reported^[@R5],[@R26]^ ([Supplementary Fig. 3a and 3b](#SD1){ref-type="supplementary-material"}). Immunofluorescence (IF) showed clear PCH foci of Atrx, which overlap with the DAPI-dense signals, in the wildtype (WT) MEF cells ([Fig. 2a](#F2){ref-type="fig"}, panels a--c), but diffused signals in the DKO MEF cells ([Fig. 2a](#F2){ref-type="fig"}, panels d--f). Re-expression of wildtype (WT) Suv39h1 (58.8%), but not the catalytically inactive mutant H324L-Suv39h1^[@R24]^ (1.4%), restores PCH localization of Atrx in DKO cells ([Fig. 2b and c](#F2){ref-type="fig"}, right panel). Recovery of H3K9me3 signals was observed only in WT-Suv39h1 positive cells ([Fig. 2c](#F2){ref-type="fig"}, left panel). These results suggest that H3K9me3 itself is essential for tethering Atrx to PCH.

Previous studies implicated the methyl CpG binding protein Mecp2 and the heterochromatin protein Hp1α in the PCH localization of Atrx. Specifically, it has been shown that Mecp2 directly interacts with Atrx, and that loss of Mecp2 disrupts Atrx PCH localization^[@R27]^. Interestingly, while Atrx PCH localization is compromised, Mecp2 remained at PCH in the DKO cells ([Fig. 2d](#F2){ref-type="fig"}), suggesting that Mecp2 is likely to be necessary but not sufficient for Atrx PCH localization. Atrx directly binds Hp1α via the conserved Hp1-interacting motif PxVxL^[@R28],[@R29]^. The deletion mutant ATRX-d/PxVxL, which lacks the Hp1-interacting motif (aa 581--594) ([Fig. 2e](#F2){ref-type="fig"}), showed a decreased PCH localization ([Fig. 2f](#F2){ref-type="fig"}), suggesting that Atrx-Hp1 interaction contributes to the localization. However, PCH localization of the catalytically inactive ATRX mutant K1600R^[@R14]^ was unaffected, indicating that PCH localization is independent of ATRX chromatin remodeling activity ([Fig. 2f](#F2){ref-type="fig"}). RNAi inhibition of Atrx did not affect Hp1α PCH localization ([Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}), suggesting that Hp1α protein acts upstream of Atrx. Atrx is also located at promyelocytic leukemia (PML) bodies via physical interaction with Daxx^[@R14],[@R30]^. Atrx remains localized to the Daxx-positive PML bodies in the DKO cells ([Fig. 2g](#F2){ref-type="fig"}), suggesting that recruitment of Atrx to PCH versus PML bodies involves distinctive mechanisms. Taken together, Atrx PCH localization appears to involve multivalent interactions that include H3K9me3 binding and physical interactions with Mecp2 and Hp1 proteins, but H3K9me3 likely plays a dominant role.

Molecular basis for H3K9 trimethylation readout by ADD~ATRX~ {#S5}
------------------------------------------------------------

To explore the molecular basis for H3 binding by ADD~ATRX~, we solved the crystal structures of ADD~ATRX~ in its free state (1.90 Å), in complex with unmodified H3~1--15~ (2.50 Å) and with H3~1--15~K9me3 (0.93 Å) ([Table 1](#T1){ref-type="table"}). The ADD~ATRX~ domain is composed of an N-terminal GATA-like "C2C2" zinc finger and a C-terminal "C4C4" imperfect PHD finger ([Fig. 3a](#F3){ref-type="fig"}). The compact fold of the ADD~ATRX~ domain originates from extensive contacts, mostly hydrophobic, between the GATA-like finger and the PHD finger, with buried surface of \~2,000 Å^2^. In our crystal structure of ADD~ATRX~ bound to unmodified H3~1--15~, we could only trace residues 1--7 of the peptide ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}), while residues 1--10 could be traced in the H3~1--15~K9me3 complex ([Fig. 3b](#F3){ref-type="fig"}). Upon complex formation, both bound H3 peptides form an anti-parallel β-sheet with the ADD~ATRX~ PHD finger ([Fig. 3a](#F3){ref-type="fig"}). The K9me3 group is inserted into a pocket formed at the junction of the GATA-like finger and the PHD finger ([Fig. 3a and b](#F3){ref-type="fig"}), associated with \~574 Å^2^ buried surface upon H3~1--15~K9me3 binding. The H3 binding surface is negatively charged, which enables favorable electrostatic recognition of the basic H3 N-terminal tail on complex formation ([Fig. 3b](#F3){ref-type="fig"}). Structural superimposition of free and peptide-bound ADD~ATRX~ revealed local conformational adjustments of loops Val178--Tyr187, Arg211--Asp217, Ile256--Gln262, as well as the N- and C-termini ([Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}), indicative of a largely pre-formed K9me3 binding pocket ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}).

The composite K9me3 binding pocket is formed by segment Tyr203--Ser210 from the GATA-like finger and Gln219--Glu225 from the PHD finger (stereo view in [Fig. 3c](#F3){ref-type="fig"}). The integrity of this pocket is stabilized by three hydrogen-bonding Gln219--Ser210, Tyr203--Glu225, and Tyr204--Arg221 inter-domain pairs ([Fig. 3c](#F3){ref-type="fig"}). One bound water molecule, hydrogen-bonded to residues Met205 and Asp207, fills in the space above the Tyr204 side chain ([Fig. 3c](#F3){ref-type="fig"}). Taken together, the above arrangements generate an exquisitely sculpted pocket with dimensions that are perfectly matched for accommodation of the bulky trimethyllysine group ([Fig. 3d](#F3){ref-type="fig"}). Unlike other classical trimethyllysine readers that usually consist of an aromatic-lined cage for higher methylation state-specific recognition^[@R31]^, the ADD~ATRX~ adopts an atypical reader pocket that contains only one aromatic residue and is otherwise rich in polar residues ([Fig. 3c and d](#F3){ref-type="fig"}). The atomic resolution structure of the monoclinic H3~1--15~K9me3 complex enables an accurate assessment of both conventional and non-conventional bonding interactions around the K9me3 group ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). Specifically, our structural analysis revealed that in addition to a collection of favorable van der Waals contacts associated with a high degree of surface complementarity, the recognition of K9me3 is facilitated by conventional hydrogen bonding between Glu225 and H3K9 backbone; cation-π interaction between the Tyr203 aromatic ring and the cationic trimethyllysine; and most strikingly, a set of carbon-oxygen hydrogen bonds engaging the ε-N-trimethyllysine group and pocket residues Tyr203, Asp207, Gln219 and Ala224 ([Fig. 3c](#F3){ref-type="fig"} and [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). These extensive conventional and nonconventional interactions likely contribute to the nearly doubling of heat generation upon H3K9me3 peptide binding, coupled with the substantially increased affinity compared to an unmethylated H3 peptide ([Fig. 1](#F1){ref-type="fig"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

Effects of H3 sequence context on the ADD~ATRX~/H3 interaction {#S6}
--------------------------------------------------------------

The recognition of the H3 tail by ADD~ATRX~ is dominated by a network of hydrogen bonds and salt bridges ([Fig. 4a](#F4){ref-type="fig"}). In addition to backbone β-sheet formation, sequence specific H3 recognition is notably contributed by 1) anchoring of the free N-terminal amine of H3 by residues Ile256, Asp258, Asn261 and Asp233; 2) unmodified H3K4 recognition by residues Asp212, Asp217 and Glu218; 3) hydrogen bonding between H3T6 and residues Gln219 and Gly227; and 4) H3K9me3 encapsulation within a composite pocket formed at the junction of the GATA-like finger and the PHD finger. The recognition of unmodified H3K4 side chain by direct hydrogen bonding and salt bridge formation with acidic residues, readily explains why the resulting increased hydrophobicity and bulkiness upon Lys4 methylation, would disrupt the above mentioned polar interactions.

The importance of H3 sequence context was further verified by ITC titrations using various synthetic H3 peptides as summarized in [Fig. 4b](#F4){ref-type="fig"}. Unmodified histone H3~1--10~ (\~3.6 μM) and longer H3~1--15~ (\~3.7μM) peptides exhibited similar binding affinities, while the binding was totally lost for H3~1--5~ or H3~5--13~K9me3 peptides. These results are consistent with the structural studies, which indicate that H3 aa 1--10 represents the minimal motif for efficient ADD~ATRX~ interaction. Notably, dual alanine extension of the H3 N-terminus, R2A, K4A, K9A mutations and K9 acetylation, substantially affect the binding as evidenced by increased disassociation constants ranging from 26.8 to 680 μM. More modest drops in binding affinities by a factor of 2 to 3, compared to the unmodified peptide, were observed upon Arg2 symmetrical or asymmetrical dimethylation, suggesting modulatory methylation crosstalk involving Arg2. Collectively, these results underscore the importance of the free N-terminus, as well as the positively charged side chains of Arg2, Lys4 and Lys9 residues for binding by the ADD~ATRX~ domain, and indicate that the binding of H3K9me3 by ADD~ATRX~ represents a cooperative process requiring multiple contributing factors for optimal recognition.

Structural comparison with other methylated H3K9 readers {#S7}
--------------------------------------------------------

Members of the 'Royal Family', such as chromo, MBT and tudor domains, as well as the ankyrin repeat^[@R32]^ have been shown to bind to histone H3K9 methyl marks primarily through an aromatic-lined cage^[@R31]^. However, previous structural analysis showed that H3 sequence motifs essential for this recognition are centralized to the segments adjacent to H3K9^[@R32]--[@R34]^. For instance, H3 segments Gln5--Ser10, Lys4--Ser10, and Ala7--Gly13 were reported to be responsible for H3 binding by the HP1 chromodomain^[@R33]^ (PDB code: 1KNE), the CHP1 chromodomain^[@R34]^ (3G7L), and the GLP ankyrin repeat^[@R32]^ (3B95), respectively ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). There is no available information to date on the impact of Lys4 methylation on this recognition^[@R5],[@R6],[@R33]--[@R35]^. Though unmodified H3K4 has been reported to contribute to the H3K9me3 peptide binding by the CHP1 chromodomain through interactions with a surface glutamate residue ([Supplementary Fig. 7c](#SD1){ref-type="supplementary-material"}, left), a role of Lys4 methylation on histone H3 binding was not experimentally tested, and a strong effect on binding affinity by Lys4 methylation was not anticipated given the open binding site and flexibility of H3K4^[@R34]^. In contrast, ADD~ATRX~ represents a novel type of H3K9me3 reader module whose binding to H3 engages an entire H3 N-terminal tail from Ala1 to Ser10, and is subjected to regulations by methylation at both Lys4 and Lys9. In addition, ADD~ATRX~ adopts a polar K9me3 "reader" pocket that is distinct from the prevalent trimethyllysine-binding aromatic cage identified in a series of reader modules including 'Royal Family' members and PHD fingers^[@R31]^, thereby shedding light on potential existence of other methyllysine readers with similar recognition strategy.

Integrity of ADD ensures H3 binding and PCH localization of ATRX {#S8}
----------------------------------------------------------------

To determine the importance of the K9me3 binding pocket, Tyr203, Tyr204, and Asp207 were substituted by alanine, and Gln219 was replaced by proline as it occurs in an individual with ATR-X syndrome^[@R13]^. While D207A showed a slight binding to H3K9me3, Y203A and Y204A showed severely compromised binding to H3K9me3, and Q219P showed no detectable binding ([Fig. 5b](#F5){ref-type="fig"}). Quantitative ITC titration of purified Y203A mutant using H3~1--15~K9me3 peptide revealed a Kd of 4.6 μM and a ΔH of −4.7 kcal/mol, which is comparable to the wild type ADD~ATRX~ binding to unmodified H3 peptide, indicative of a specific disruption of K9me3 binding ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"} and [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). In addition, the above mutants also failed to bind to nucleosomes, which are physiological substrates for Atrx ([Fig. 5c](#F5){ref-type="fig"}), demonstrating the importance of the K9me3 binding pocket. Interestingly, residues accommodating K9me3 in ADD~ATRX~, including Tyr203, Tyr204 and Gln219, are not conserved in the ADD domains of DNMT3A, B, and L, whereas, the residues responsible for K4me0 recognition, such as Asp212, are well conserved ([Fig. 5a](#F5){ref-type="fig"} and [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}). Consistently, although K4me0 recognition represents a common function of ADD~ATRX~ and ADD~DNMT3s~, ADD~DNMT3s~ lacks the H3K9me3-binding pocket ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}), thereby defining H3K9me3 recognition as a unique function of the ADD~ATRX~.

Next, we determined whether compromised H3 binding is a general consequence of mutations associated with ATR-X syndrome. Four additional human mutations in AD-D~ATRX~, H189N, P190A, R246C and E252L, were analyzed ([Fig. 5a](#F5){ref-type="fig"}). All four mutants exhibited markedly reduced binding to H3 peptides ([Fig. 5d](#F5){ref-type="fig"}) and nucleosomes ([Fig. 5e](#F5){ref-type="fig"}). A previous NMR study showed that folding of ATRX proteins carrying R246C and Q219P mutations remains intact, while another patient mutation, H189D, leads to a disruption of proper folding^[@R36]^. Our results, together with these observations, suggest that loss of H3 binding caused by patient mutations could be due to either local structural changes at the H3 binding interface or a disruption of overall folding of ADD~ATRX~. For the K9me3-pocket mutants, especially Y203A, Y204A, and D207A, their binding with the unmethylated H3 peptide was largely unaffected, suggesting that these mutations did not affect the overall structure of ADD~ATRX.~

To determine the role of ADD~ATRX~ in PCH localization, we examined subnuclear distribution of HA-tagged WT and mutant ATRX in NIH3T3 cells by IF. HA-tagged ATRX (HA-ATRX) showed clear PCH foci ("punctate") in more than 80% of the interphase cells ([Fig. 5f](#F5){ref-type="fig"}, panels a-c). However, HA-ATRX carrying H3K9me3 binding defective or patient point mutations showed either diffused ([Fig. 5f](#F5){ref-type="fig"}, panels d-f) or punctate signals ("abnormal puncta") ([Fig. 5f](#F5){ref-type="fig"}, panels g--i), which do not overlap with the DAPI-dense signals. The quantification of the IF analysis is shown in [Fig. 5g and h](#F5){ref-type="fig"}. Patient mutations in ADD~ATRX~ did not affect PML body localization of ATRX ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}), suggesting that ADD~ATRX~ is specifically required for anchoring ATRX onto PCH. Previous studies showed that patient mutations result in a decreased protein level of ATRX^[@R36]^. Collectively, ADD~ATRX~/H3 interaction plays an important role in localizing ATRX to PCH, and patient mutations in ADD~ATRX~ disrupt this targeting mechanism and decrease the stability of ATRX protein.

DISCUSSION {#S9}
==========

In this report, we provided ample evidence demonstrating that ADD~ATRX~ is a novel H3K9me3 recognition module, which senses the methylation states at both H3K9 and H3K4. Co-crystal structures at atomic resolution revealed a fascinating composite and atypical H3K9me3 binding pocket formed between the GATA- and the PHD- fingers of ADD~ATRX~. Point mutations in this binding pocket substantially compromised AD-D~ATRX~/H3K9me3 binding *in vitro* and the PCH localization of ATRX *in vivo*. Complementing the structural analysis, genetic studies provided further support that H3K9me3 is critical for the PCH localization of Atrx. Importantly, ATRX patient mutations in ADD~ATRX~ impaired the PCH localization, further indicating the importance of the ADD domain as a critical determinant of proper ATRX localization *in vivo*.

PCH is fundamental for sister chromatid cohesion, and proper chromatid cohesion indeed requires the H3K9me3 HMTases^[@R37],[@R38]^. Loss of Atrx has been shown to result in a chromosome segregation defect due to the attenuated cohesion and congression of sister chromatids^[@R39]^, which may lead to increased apoptosis and a reduced number of neurons in the brain^[@R39],[@R40]^. Thus, our findings suggest that Atrx is an important component in the Suv39h/H3K9me3 pathway that is required for faithful chromosome segregation ([Fig. 6](#F6){ref-type="fig"}).

While chromosome missegregation would suggest a role for Atrx during M-phase, compromised heterochromatin replication in S-phase could also cause mitotic catastrophe as observed for the loss of other chromatin modifying proteins^[@R41],[@R42]^. Atrx is recruited to the telomere during S-phase and loss of Atrx results in a DNA damage response and de-repression of telomere-associated RNA^[@R18],[@R43]^. Notably, Atrx coordinates deposition of a variant histone with a histone H3.3-specific chaperone Daxx^[@R18],[@R44],[@R45]^. H3.3 deposition at PCH and telomeres^[@R44],[@R45]^ may contribute to heterochromatin formation. Taken together, Atrx may be required for faithful replication of both telomeric and pericentromeric heterochromatin.

Importantly, our structural research has identified an unanticipated mode of histone mark recognition, namely the utilization of integrated modules to generate a composite and atypical binding pocket at the interface between the GATA and PHD fingers of ATRX for Kme3 recognition. The concept of integrated modules acting as a single functional unit was recently highlighted in the structures of DPF3b double PHD finger bound to the H3K14ac mark^[@R46]^ and the PHD-Bromo cassette of TRIM24 bound to the H3K23ac mark^[@R47]^, though in each case the Kac mark was recognized solely by a single module. Taken together, these findings call attention to the role of integrated modules and our newly proposed concept of composite reader pockets, which we anticipate will be increasingly identified amongst various epigenetic regulators associated with histone mark recognition and readout.

In summary, we have uncovered the function of ADD~ATRX~ as a recognition motif for the distinctive histone methylation pattern at PCH, representing the first report linking a novel histone methylation sensing mechanism to human brain function. Our study may also open a new avenue for therapeutic intervention of ATR-X syndrome.

ACCESSION CODES {#S10}
===============

The atomic coordinates and structure factors for the ADD~ATRX~ domain in the free and the peptide bound forms have been deposited into Protein Data Bank under accession code 3QLN (free), 3QLC (H3~1--15~ complex), 3QL9 (H3~1--15~K9me3 complex, monoclinic form) and 3QLA (H3~1--15~K9me3 complex, hexagonal form).

METHODS {#S11}
=======

Expression plasmids {#S12}
-------------------

Human ATRX was PCR-amplified from cDNA libraries prepared from HeLa cells and lymphocyte, using Phusion polymerase (Finnenzymes), and cloned into a Gateway entry vector pENTR-D-Topo (Invitrogen). A fully sequenced ATRX-WT cDNA, as well as a series of point mutants, and a deletion mutant d/PxVxL generated by PCR-based mutagenesis, were transferred into Gateway destination vectors pCS2-3HA, which are designed to fuse HA-tags to N-terminus of protein. The ADD~ATRX~ domain with its flanking amino acids, positioning 162--293, was cloned into pGEX4T-1 (GE Healthcare) for expression and purification as GST-fusion proteins using *E. coli*. Point mutations in ADD domain associated with ATR-X syndrome were introduced by PCR-based targeted mutagenesis. Numbering of amino acid residues is based on the Gen-Bank accession numbers NM_000489.3 and NP_000480, for mRNA and protein, respectively.

For crystallographic and ITC binding assays, an ADD~ATRX~ construct corresponding to ATRX fragment 167--289 was PCR-amplified from human ETS IMAGE clone: 4695967, and cloned into a modified pGEX6P-1 vector (GE Healthcare) with an N-flanking artificial sequence "GPLGSM" from the vector. The expressed ADD domain based on this human ETS clone contains two amino acid variations, K251R and F284Y, compared to the sequence of NP_000480.

Protein purification and peptide pulldown assays {#S13}
------------------------------------------------

GST-fused ADD domains were expressed in *E. coli* strain, purified using glutathione-affinity sepharose (GE Health-care). For the histone peptide pull-down assay, 3 μg of purified proteins, WT as well as the syndrome-associated mutants N179S, H189N, P190A, R246C, and E252L, were incubated with 0.1 μg of biotinylated histone peptide in 100 μl of the binding buffer A (50 mM Tris-HCl pH7.5 containing 150 mM NaCl, and 0.05% (v/v) NP-40) for overnight at 4°C. For the K9me3-binding-defective mutants, Y203A, Y204A, D207A, and Q219P, binding reactions (in parallel with WT) were carried out in modified buffer A containing 500 mM NaCl for 3 hours at 4°C. Protein-peptide complexes were pulled down with streptavidin-conjugated affinity resin (Upstate), washed 5 times using the binding buffer A, and bound proteins are detected as histone binding assay above. Nucleosomes mainly comprised of mono- and di- units were prepared from HeLa cells following the conventional protocol^[@R48]^. Nucleosomes and GST-ADD domains were incubated in binding buffer A, pulled-down by glutathione sepharose resin, washed by binding buffer A and analyzed by Western blot analysis using pan-H3 Abs (Abcam, 1791--100) and anti-GST antibody (Santa Cruz, sc-138).

ADD~ATRX~ used for ITC and crystallization was expressed in the *E. coli* host cell Rossetta2 (Novagen) induced overnight by 0.4 mM isopropyl β--D--thiogalactoside at 20°C in the LB medium supplemented with 0.1 mM ZnCl~2~. The harvested cells were suspended in 0.4 M KCl, 20 mM Tris pH 7.5. After cell lysis and centrifugation, the GST--fusion protein was purified by GST affinity column, followed by tag cleavage using PreScission protease (GE Healthcare). The ADD~ATRX~ was then directly separated from the digestion mixture by size--exclusion chromatography on Superdex^™^ 75 (GE Healthcare) under the elution buffer: 0.4 M KCl, 20mM Tris, pH 7.5, 5 mM DTT. The resultant peak of AD-D~ATRX~ was then concentrated to \~15--40 mg ml^−1^, split into small aliquots and frozen in liquid nitrogen for future use.

Isothermal titration calorimetry {#S14}
--------------------------------

Calorimetric experiments were conducted at 25.0°C with a MicroCal^™^ iTC200 instrument (GE Healthcare). The ADD~ATRX~ samples were dialyzed against the buffer containing 25 mM HEPES-NaOH, pH 7.5, 100 mM KCl, and 5 mM β-mercaptalethanol. Protein concentration was determined by absorbance spectroscopy at 280 nm with an extinction coefficient of 19940 M^−1^ cm^−1^. Peptides were quantified either by the absorbance of an added C-terminal Tyr residue (Tyr ε~280~=1,280 M^−1^cm^−1^), or by weighing in large scale for those without an additional tyrosine residue. Acquired calorimetric titration data were analyzed using software Origin 7.0 (GE Health-care) based on the 'One Set of Sites' fitting model.

X-ray crystallographic studies {#S15}
------------------------------

All crystals were grown by the sitting-drop vapor diffusion method under 4°C. Detailed crystallization conditions are listed in [supplementary section](#SD1){ref-type="supplementary-material"}. Diffraction data were collected under cryo-conditions using 15--20% (v/v) glycerol as the cryoprotectant. An anomalous data set at zinc peak of the free ADD~ATRX~ crystal was collected at the beamline X-29 at the National Synchrotron Light Source (NSLS) of Brookhaven National Laboratory in New York. A native data set of H3~1--15~-ADD~ATRX~ complex was collected at the beamline ID24-C at Advanced Photon Source (APS) of Argonne National Laboratory in Illinois. As for the H3~1--15~K9me3 complex crystals, diffraction data were collected at beamline 3W1A of Beijing Synchrotron Radiation Facility (BSRF) at Beijing, China. All diffraction data were processed with the HKL2000 suite^[@R49]^ and data processing statistics are summarized in [Table 1](#T1){ref-type="table"}.

The structure of free ADD~ATRX~ was determined by zinc SAD (Single-wavelength Anomalous Dispersion) method using the PHENIX software suite^[@R50]^. The remaining complex crystal structures were solved by molecular replacement with the program MOLREP^[@R51]^ of the CCP4 program suite^[@R52]^ using the free ADD~ATRX~ structure as the search model. Model building and refinement were undertaken with COOT^[@R53]^ and PHENIX^[@R50]^. Detailed structural determination procedures are described in [supplementary section](#SD1){ref-type="supplementary-material"} ([Supplementary Methods](#SD1){ref-type="supplementary-material"}) and structural refinement statistics are summarized in [Table 1](#T1){ref-type="table"}.

Immunofluorescence microscopy {#S16}
-----------------------------

Staining and observation were performed as described previously^[@R54]^. Primary antibodies were used at the following dilutions in the permeabilization buffer: 1:100 dilution was applied for anti-HA (Covance, monoclonal HA.11), anti-DAXX (Santa Cruz, sc-8043), anti-H3-K9me2 (Upstate, 07--441), anti-H3-K9me3 (Upstate, 07--442) Abs, anti-PML (Santa Cruz, sc-5621), monoclonal anti-Suv39h1 (44.1: sc-23961), anti-HP1α (mAbs) (Upstate, 05-689), and 1:500 for anti-ATRX Ab (Santa Cruz, sc-15408). Alexa 594- or Alexa 488-conjugated secondary Abs (Invitrogen) was used at 1:500. Rabbit antiserum for MeCP2 was a generous gift from Dr. Greenberg lab. For the localization of HA-fused ATRX proteins, pCS2-3HA gateway destination vectors carrying HA-ATRX WT and various mutants are transfected in NIH3T3 cells using Fugene HD reagent (Roche Applied Science), and 24 hrs later, subjected to IF using anti-HA mAb as described above. Suv39h1-WT and its catalytically inactive mutant H324L expression plasmids were introduced into Suv39h1/h2 double knockout cells using Fugene HD and recombinant protein expression was detected by IF using anti-Suv39h1 mAb.
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![Methylation at K4 and K9 inversely regulates interaction between AD-D~ATRX~ and histone H3\
(**a**) ATRX patient mutations (circles) are predominantly found in either the ADD or the SNF2 ([S]{.ul}ucrose [N]{.ul}on [F]{.ul}ermenting)-type ATP-dependent chromatin remodeling domain. (**b**) ADD~ATRX~ interacts with the unmodified H3 peptide (1--21 aa) (lane 3), and the interaction was enhanced by K9 methylation (lanes 4--6). (**c--f**) Experimental ITC titration curves are displayed in panel **c** for unmodified H3 (peptide to buffer control shown in the top), and panel **d** for H3K9me3 peptide. The fitting curves and the calculated binding affinities are listed in panels **e** and **f**. Methylation at K4 (panel **e**) and K9 (panel **f**) displayed entirely different effects on the binding affinity. Detailed peptide sequences and complete ITC fitting parameters are summarized in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.](nihms282064f1){#F1}

![Atrx is recruited to PCH by Suv39h1/2-mediated H3K9 trimethylation\
(**a**) Atrx fails to locate on PCH in Suv39h1/h2 double knock-out (DKO) cells. (**b** and **c**) Suv39h1-WT but not a catalytically inactive mutant Suv39h1-H324L restores the PCH localization of Atrx in DKO cells. Suv39h1-WT (panels a to d) and Suv39h1-H324L (panels e to h) were expressed in DKO cells. (**c**) Quantification of presence or absence of H3K9me3 signal in the Suv39h1-positive cells (left panel), and punctate PCH localization or diffused distribution of Atrx (right panel). (**d**) Mecp2 is localized at PCH in both WT- (panels a to c) and DKO- (panels d to f) MEF cells. (**e**) Schematic diagram of ATRX proteins used for testing their localization. (**f**) Deletion of PxVxL motif resulted in partial loss of PCH localization. Subnuclear distribution of ATRX proteins represented in ([Fig. 4f](#F4){ref-type="fig"}) was quantified. (**g**) Targeting of Atrx (panels b and f) to Daxx-positive PML bodies (panels a and e) is not affected in Suv39h DKO cells (panels e to h).](nihms282064f2){#F2}

![Molecular basis for H3K9me3 recognition by ADD~ATRX~\
(**a**) Ribbon representation of ADD~ATRX~ domain in complex with H3~1--15~K9me3 peptide. ADD~ATRX~ domain is a hybrid of a GATA-like zinc finger (cyan) and a PHD finger (magenta). Three zinc ions are depicted as spheres and the H3 peptide is colored yellow with key residues Lys4 and K9me3 shown in stick representation. (**b**) Surface electrostatic view of ADD~ATRX~ domain in complex with H3~1--15~K9me3 peptide, color-coded with red representing negatively-charged and blue positively-charged potentials. The Fo-Fc omit map was contoured at 3.5 σ level for the bound H3 peptide. (**c**) Stereo view of the K9me3-binding pocket. The GATA-like segment Tyr203--Ser210 and the PHD finger segment Gln219---Glu225 are color-coded in cyan and magenta, respectively. Blue dotted lines refer to nonconventional C-H:O hydrogen bonds. (**d**) A snug fit of the bulky trimethyllysine group inserted into the reader pocket of ADD~ATRX~.](nihms282064f3){#F3}

![Effect of H3 sequence context on ADD~ATRX~ binding\
(**a**) Details of H3-ADD~ATRX~ interaction. Histone H3 Ala1--Ser10 containing K9me3 modification is depicted as yellow sticks. ADD~ATRX~ is shown as light blue ribbons with key residues that interact with H3 peptide shown as pink sticks. Red dotted lines denote hydrogen bonds. Three zinc ions and water molecules are depicted as large blue and small red spheres, respectively. (**b**) ITC titration fitting curves and the binding constants of synthetic H3 peptide variants to WT-ADD~ATRX~. R2A, K4A, K9A: Arg2, Lys4, Lys9 to alanine substitution, respectively; AAH3: H3 N-terminal double alanine extension; R2me2s: Arg2 symmetrical dimethylation; R2me2a: Arg2 asymmetrical dimethylation; K9me3: Lys9 trimethylation; K9ac: Lys9 acetylation; n.d., not determined. Detailed peptide sequences and complete ITC fitting parameters are summarized in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.](nihms282064f4){#F4}

![Mutations in ADD~ATRX~ compromise histone binding and targeting of ATRX onto PCH\
(**a**) Alignment of the ADD domains. Hs: Homo sapiens (human), Dr: Danio rario (zebrafish), Xt: Xenopus tropicalis (frog). Conserved cysteines are presented as red letters. (**b**) Mutations in the K9me3-pocket limit the binding of ADD~ATRX~ to H3 peptides methylated at Lys9. (**c**) Mutations in the K9me3-pocket disrupt binding to nucleosomes. GST alone (lane 1) or GST-ADD~ATRX~ WT (lane 2) as well as mutants (lanes 3 to 6) were incubated with nucleosomes. (**d** and **e**) Four patient mutations resulted in defective H3 peptide binding (**d**) and nucleosome binding (**e**). (**f**) Representative images of subnuclear distribution of recombinant ATRX proteins in NIH3T3 cells. (**g** and **h**) Quantification of the distribution patterns is shown for the four K9me3-pocket mutants (**g**) and additional four syndrome-associated mutants (**h**).](nihms282064f5){#F5}

![Model of the mechanism underlying ATR-X syndrome caused by the mutations in ADD~ATRX~\
Atrx is recruited on PCH via interaction between ADD and H3K9me3 generated by Suv39h HMTs. Physical associations of Hp1/Atrx and Mecp2/Atrx support the PCH anchoring of Atrx. Patient mutations in ADD disrupt H3K9me3 binding; then Atrx falls off from PCH. Loss of Atrx from PCH may leads to compromised higher-order structure of PCH, followed by chromosome missegregation and apoptosis in neuroprogenitor cells.](nihms282064f6){#F6}

###### 

Data collection, phasing and refinement statistics

                               Free                                                   ADD~ATRX~--H3~1--15~   ADD~ATRX~--H3~1--15~K9me3   
  ---------------------------- ------------------------------------------------------ ---------------------- --------------------------- -----------------------
  **Data Collection**          Zn-SAD                                                 Native                 Native                      Native
  Space group                  *P*3~2~                                                *P3~2~21*              *P6~5~*                     *C2*
  Cell dimensions                                                                                                                        
   *a, b, c (Å)*               74.2, 74.2, 54.1                                       80.6, 80.6, 136.1      66.7, 66.7, 131.6           83.7, 39.5, 41.1
   *α, β, γ (°)*               90, 90, 120                                            90, 90, 120            90, 90, 120                 90, 111.2, 90
                               *Peak*                                                                                                    
  Wavelength (Å)               1.2827                                                 0.9795                 0.9792                      0.9792
  Resolution (Å)               50--1.9 (1.93--1.90)[\*](#TFN1){ref-type="table-fn"}   50--2.5 (2.56--2.50)   50--1.6 (1.63--1.60)        50--0.93 (0.95--0.93)
  *R*~sym~ (%)                 6.3 (55.4)                                             6.3 (53.2)             8.3 (56.6)                  6.7 (57.0)
  *I/*σ*I*                     43.6 (4.0)                                             40.4 (4.0)             23.3 (2.7)                  35.5 (3.5)
  Completeness (%)             99.9 (100.0)                                           99.7 (100.0)           98.5 (97.3)                 93.1 (88.1)
  Redundancy                   5.6 (5.5)                                              12.4 (7.7)             9.7 (9.3)                   8.5 (8.2)
  **Refinement (F\>0)**                                                                                                                  
  No. reflections (overall)    26159                                                  18264                  41649                       76594
  No. refelctions (test set)   1997                                                   1473                   2093                        3831
  Twinning fraction            0.408                                                                                                     
  *R~work~*/*R~free~* (%)      12.7/15.8                                              19.4/24.1              15.7/17.9                   12.2/13.1
  No. non--H atoms                                                                                                                       
   Protein                     1935                                                   2016                   1976                        1085
   Ligand/ion                  --/6                                                   106/6                  176/6                       93/3
   Water                       334                                                    114                    471                         240
  *B*-factors (Å^2^)                                                                                                                     
   Protein                     35.5                                                   51.1                   18.6                        8.1
   Ligand/ion                  --/37.0                                                60.7                   21.6/12.1                   12.9/3.8
   Water                       38.0                                                   45.5                   31.5                        14.0
  R.m.s. deviations                                                                                                                      
   Bond lengths (Å)            0.006                                                  0.009                  0.015                       0.020
   Bond angles (°)             0.92                                                   1.13                   1.37                        1.41

Each data set was collected from a single crystal; values in parentheses are for highest resolution shell.
